These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 16470607

  • 1. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
    Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.
    Cancer; 2006 Mar 15; 106(6):1320-5. PubMed ID: 16470607
    [Abstract] [Full Text] [Related]

  • 2. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
    Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ.
    J Clin Oncol; 2004 Mar 01; 22(5):927-34. PubMed ID: 14990649
    [Abstract] [Full Text] [Related]

  • 3. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
    Huang H, Cai Q, Lin T, Lin X, Liu Y, Gao Y, Peng R.
    Expert Opin Pharmacother; 2009 Oct 01; 10(15):2399-406. PubMed ID: 19761353
    [Abstract] [Full Text] [Related]

  • 4. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
    Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ.
    Breast Cancer Res Treat; 2004 Dec 01; 88(3):209-15. PubMed ID: 15609123
    [Abstract] [Full Text] [Related]

  • 5. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.
    Lim ST, Fei G, Quek R, Lim LC, Lee LH, Yap SP, Loong S, Tao M.
    Eur J Haematol; 2007 Aug 01; 79(2):132-7. PubMed ID: 17635237
    [Abstract] [Full Text] [Related]

  • 6. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma.
    He YF, Li YH, Wang FH, Jiang WQ, Xu RH, Sun XF, Xia ZJ, Huang HQ, Lin TY, Zhang L, Bao SP, He YJ, Guan ZZ.
    Ann Hematol; 2008 Jun 01; 87(6):481-5. PubMed ID: 18299831
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.
    Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ.
    Ann Hematol; 2004 May 01; 83(5):270-5. PubMed ID: 15060745
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Endo T, Sakai T, Fujimoto K, Yamamoto S, Takashima H, Haseyama Y, Nishio M, Koizumi K, Koike T, Sawada K.
    Bone Marrow Transplant; 2001 Feb 01; 27(4):433-6. PubMed ID: 11313673
    [Abstract] [Full Text] [Related]

  • 12. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
    Mimura N, Tsujimura H, Ise M, Sakai C, Kojima H, Fukai K, Yokosuka O, Takagi T, Kumagai K.
    Rinsho Ketsueki; 2009 Dec 01; 50(12):1715-9. PubMed ID: 20068280
    [Abstract] [Full Text] [Related]

  • 13. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.
    Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL, Chen PJ.
    Hepatology; 2008 Mar 01; 47(3):844-53. PubMed ID: 18302293
    [Abstract] [Full Text] [Related]

  • 14. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy--a prospective case series.
    Vassiliadis T, Garipidou V, Tziomalos K, Perifanis V, Giouleme O, Vakalopoulou S.
    Am J Hematol; 2005 Nov 01; 80(3):197-203. PubMed ID: 16247746
    [Abstract] [Full Text] [Related]

  • 15. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations.
    Picardi M, Pane F, Quintarelli C, De Renzo A, Del Giudice A, De Divitiis B, Persico M, Ciancia R, Salvatore F, Rotoli B.
    Haematologica; 2003 Nov 01; 88(11):1296-303. PubMed ID: 14607759
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.
    Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.
    J Clin Gastroenterol; 2009 Nov 01; 43(5):496-8. PubMed ID: 19247200
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.